The mechanism of inhibition of eukaryotic by itself has no effect on the binding of various forms of DNA to yeast DNA topoisomerase II. When both and ATP are present, however, the enzyme is converted to the closed form, as evidenced by the SV8 endoproteinase cleavage pattern as well as the characteristics of the DNAenzyme complexes. These results suggest that bis(2,6-dioxopiperazines) act by stabilizing eukaryotic DNA topoisomerase II in the closed-clamp form and preventing it from opening again. 
Eukaryotic DNA topoisomerase II [DNA topoisomerase (ATP-hydrolyzing), EC 5 .99. 1.3 ] is a member of the type II DNA topoisomerase family, which catalyzes the ATPdependent transport of one double-stranded DNA segment through another (1) (2) (3) . In the past decade, a number of anticancer drugs have been found to target the enzyme (4) (5) (6) (7) . One class of these drugs, including doxorubicin, amsacrine, etoposide, and teniposide, was shown to interfere with the DNA-rejoining activity of the enzyme. Such a drug binds to an enzyme-DNA complex and stabilizes the covalent complex in which a pair of DNA phosphodiester bonds, one in each strand of the DNA duplex, are severed, and the 5' phosphoryl group of each broken DNA strand is covalently linked to a protein tyrosyl residue-Tyr-805 in the case of human DNA topoisomerase 11a (8) . Drugs that stabilize the covalent DNA-DNA topoisomerase reaction intermediates are often referred to as DNA topoisomerase poisons, as they act by converting these normal cellular enzymes into DNAdamaging agents (5, 9) .
There are a number of DNA topoisomerase II-targeting drugs that apparently do not stabilize the covalent intermediate. Bisdioxopiperazine derivatives including and are among the newest members of this category (10, 11) , which also includes fostriecin (12) , merbarone (13) , and aclarubicin (14) . Other than their inhibition of eukaryotic DNA topoisomerase II-catalyzed topological transformations of DNA rings, there is little information on the mechanisms by which these drugs affect eukaryotic DNA topoisomerase II.
Recently, a protein clamp model has been proposed for eukaryotic DNA topoisomerase II (15) . In this model, a homodimeric enzyme acts as an ATP-modulated protein clamp: ATP-binding closes the two jaws of the clamp, and hydrolysis of the bound ATP precedes the reopening of the clamp. As a DNA-bound protein clamp closes its jaws, it can capture a second DNA segment, termed the "T-segment," and transport it through an enzyme-mediated gate in the bound DNA, termed the "G-segment." By using a nonhydrolyzable (3,'t-imido analog of ATP, adenosine 5'-[,By imido]triphosphate (AMP-P[NH]P), it was shown that the binding of the analog to yeast Saccharomyces cerevisiae enzyme triggers a concerted conformational change of the enzyme, which is detectable by the switching of a Staphylococcus aureus strain V8 (SV8) endoproteinase-sensitive site at Glu410 to a new site at Glu-680 (16, 17 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Nuclear), SV8 endoproteinase (Sigma), hexokinase (Worthington), and GF/C glass-fiber filters (Whatman).
Mapping of SV8 endoproteinase cleavage sites was done by the procedures described previously (16) , and ATPase assays were done by thin-layer chromatography as described (20) . All other methods have been described by Roca and Wang (15) . RESULTS ICRF-193 by Itself Has Little Effect on DNA Binding by Yeast DNA Topoisomerase HI. To determine the step or steps at which the bisdioxopiperazine anticancer drugs inhibit the action of eukaryotic DNA topoisomerase II, binding of DNA by the enzyme was measured in the presence and absence of one of the more potent members of this family, ICRF-193. The results of a filter-binding experiment (15) are shown in Fig. 1 . Lane 1 contained the DNA by itself upon filtration through a glass-fiber filter. As expected, nearly all DNA, the bulk of which in the supercoiled form (denoted by S in the figure) and a small fraction in the nicked circular form (denoted by N), was found in the filtrate. Eluting the filter with a buffer containing 1 M NaCl showed little DNA in the wash (lane 2). In the presence of yeast DNA topoisomerase II, DNA retention on the filter was apparent; upon washing with 1 M NaCl, which dissociates the DNA from the filterbound DNA-enzyme complex unless a circular DNA is topologically linked to an enzyme in its closed-clamp form (15) , a large fraction of the DNA retained on the filter was found in the wash (lanes 3 and 4). The relative amounts of unbound nicked and supercoiled DNA in the filtrate shown in lane 3 indicate that the enzyme binds preferentially the supercoiled form, as has been observed (15, 21, 22) at 300C in 50 mM TrisHCl, pH 8/50 mM KCI/8 mM MgCl2/7 mM 2-mercaptoethanol/100 j&g of bovine serum albumin per ml. ATP was then added to 1 mM, and incubation was continued for 10 min. NaCl was then added to the mixture to 1 M final concentration, and the mixture was passed through a glass-fiber filter. As shown in lanes 1 and 2 of Fig. 2 , most of the DNA was retained on the filter, indicating that the protein-DNA complex that was formed under these conditions is stable in 1 M NaCl; as expected, the filter-bound DNA was released upon eluting the filter with 1% sodium dodecyl sulfate (SDS) (lane 2). No salt-stable complex was observed when either ATP or ICRF-193 was omitted in this experiment ( Fig. 1 and ref. 16 ).
Reversing the order of incubation of the enzyme-DNA complex with ICRF-193 and ATP had no effect on the formation of the salt-stable complex; a 10-min incubation with ATP followed by a 10-min incubation with the drug (Fig.  2 , lanes 5 and 6) yielded the same results described above (Fig. 2, lanes 1 and 2) . When the enzyme was first incubated with both ATP and ICRF-193, however, the subsequent addition of plasmid DNA yielded no salt-stable complex: all DNA was found in the 1 M salt filtrate (lane 3) and none in the SDS wash (lane 4). Furthermore, whereas in the previous two cases the DNA was converted to the relaxed form and thus migrated as a ladder of bands ( of 50 mM Tris HCl, pH 8/50 mM KC1/8 mM MgCl2/7 mM 2-mercaptoethanol/100 ,g of bovine serum albumin per ml was first incubated at 30°C for 10 min and then filtered through a glass-fiber filter as described (15) . The filter was then eluted with 1 M NaCl. DNA was recovered from the filtrate and eluent and was analyzed in lanes 1 and 2, respectively. A second reaction mixture, identical to the one described but containing in addition 200 ng of yeast DNA topoisomerase II, and a third reaction mixture, identical to the second one but containing in addition 100 IMM were similarly processed and analyzed in lanes 3-6. S, supercoiled DNA; N, nicked circular DNA. Tris'HCl, pH 8/150 mM KC1/8 mM MgCl2/7 mM 2-mercaptoethanol/100 Ag of bovine serum albumin per ml/i mM ATP/100 AM . In lanes 1 and 2, all components except ATP were first mixed and incubated for 10 min at 30°C and ATP was then added; after an additional 10 min at 30°C, NaCl was added to 1 M final concentration, and the solution was filtered through a glass-fiber filter, which was then eluted with 1% sodium dodecyl sulfate as described (15) . DNA recovered from the filtrate and eluent was analyzed in lanes 1 and 2, respectively. In lanes 3 and 4, all components except DNA were incubated first, and incubation was continued after the addition of DNA; otherwise, the reaction mixture was processed as described above. DNA recovered from the filtrate and from the eluent was analyzed in lanes 3 and 4, respectively. Material in lanes 5 and 6 was the same as described for the other pairs of lanes, except that incubation was first carried out in the absence ofICRF-193 and then continued after its addition. R, relaxed circular DNA; S, supercoiled DNA. [a-32P]ATP with a specific activity of -20 mCi/mmol (1 Ci = 37 GBq) was then added to each reaction mixture to a final concentration of 1 mM, and aliquots of the reaction mixtures incubated at 30°C were sampled at various times and quenched for the determination of the percentage of ATP hydrolyzed. As shown by data in Fig. 3, ICRF-193 , to initiate the formation of the salt-stable enzyme-plasmid DNA complex. The reaction mixture was split into two equal portions and incubated at 30°C for 10 min. One unit of hexokinase, which phosphorylates glucose and converts ATP to ADP in the process, was added to one. After an additional 20 min at 30°C, NaCl was added to each reaction mixture to 1 M, and filtration through glass-fiber filters and elution with 1% SDS were then carried out as before.
In both the hexokinase-treated sample and the untreated control, the presence of the salt-stable complex was evident, as little DNA was found in the 1 M salt filtrate and most of the input DNA came offthe filter in the SDS wash (results not shown). Analysis of the reaction mixtures with and without hexokinase showed that in the hexokinase-treated sample, ATP was converted to ADP and no detectable amount ofATP remained; in the sample without hexokinase, the bulk of the nucleotide remained as ATP and only a trace was present as ADP. To rule out a trivial interpretation of the hexokinase results that the presence of glucose or hexokinase might inhibit DNA-bound yeast DNA topoisomerase II and thus trap the complex in the salt-stable form, control experiments were carried out in which ICRF-193 and either hexokinase or glucose were omitted from the complete reaction mixture. The samples were processed as before, and a second supercoiled DNA 10 kb in size was added to the reaction mixtures after the second incubation. After a final 10-min incubation at 30°C, the samples were analyzed by agarose gel electrophoresis. In either case, the second supercoiled DNA was found to be relaxed, showing that yeast DNA topoisomerase II is not inactivated by hexokinase or glucose.
Yeast follows. Reaction buffer (50 IAI) containing 50 mM Tris * HCI, pH 8/8 mM MgCl2/7 mM 2-mercaptoethanol/5 pg of bovine serum albumin/ 150 mM KCI, 10 pg of supercoiled DNA and 10 pg of immunotagged enzyme was supplemented with the drug or nucleotide as specified above and incubated at 30°C for 10 min. Two microliters of 1 M NH4HCO3 containing 0.1 ug of SV8 endoproteinase was added to each reaction mixture, and all samples were incubated at 30°C for 30 min. Proteolysis was stopped by the addition of an equal volume of a sodium dodecyl sulfate/polyacrylamide gel electrophoresis loading buffer. Samples were kept in a boiling water bath for 5 min before loading on the gel. Following electrophoresis, the resolved protein bands were blot-transferred to a nylon membrane and immunostained with a monoclonal antibody specific to the c-myc epitope (16) . A and B, proteolytic cleavage at the carboxyl sides of Glu-410 and Glu-680, respectively. Biochemistry: Roca et A Purified yeast DNA topoisomerase II immunotagged with a decapeptide epitope of the human c-myc protein after amino acid 1171, which is catalytically fully active (16, 23) , was used in this experiment to facilitate the mapping of proteolytic cleavage sites (16) . In the presence of ATP alone (Fig. 4, lane 1) or (Fig. 4, lane 3) , proteolytic cleavage by SV8 endoproteinase occurs mainly at site A, which has been mapped previously to the carboxyl side of Glu-410 (16) . In the presence of a combination of ATP and ICRF-193 (Fig. 4, lane 4) , however, the endopeptic cleavage site is predominantly at site B-the same as when AMP-P[NH1P was present (Fig. 4, lane 2) . Previously, site B has been mapped to the carboxyl side of (16 (Fig. 5, lane 4) . Complete relaxation of the DNA occurred, however, when the reaction mixture was incubated for an additional 10 min following a 1:9 dilution of the drug (Fig. 5, lane 5) . Dilution of the initial drug concentration from 3 juM to 0.3 pM (Fig. 5, lanes 6 and 7) , or from 10 ,uM to 1 IuM (Fig. 5, lanes 8 and 9) , also showed that more supercoiled DNA became relaxed upon diluting the inhibitor. Total reversal of inhibition by the drug was not achieved in these experiments, however; some supercoiled DNA substrate remained, for example, in the sample first incubated with 3 ,uM ICRF-193 and then diluted to an ICRF-193 final concentration of 0.3 PM (Fig. 5, lane 7) , whereas no supercoiled substrate was detectable if the drug was always present at 0.3 jiM (Fig. 5, lane 2) thus, the DNA in the final salt-stable complex was found to be in the relaxed rather than the original supercoiled form (Fig. 2, lanes 1 and 2) .
Once the dioxopiperazine drug binds to the locked proteinclamp, however, ATP is apparently not needed to maintain the closed state ofthe clamp. Removal ofATP by hexokinase from the reaction mixture has no effect on the salt-stable yeast DNA topoisomerase I-plasmid DNA complex, in which the enzyme is believed to be in the closed-clamp form.
For anticancer drugs targeting eukaryotic DNA topoisomerase II, cytotoxicity can be a result of two different mechanisms. Drugs such as etoposide and amsacrine act by their trapping of the covalent enzyme-DNA complexes, and cytotoxicity of these drugs is closely related to breakage of double-stranded DNA, for example as a result ofthe collision between replication forks and DNA-enzyme-drug ternary complexes (5, (24) (25) (26) ; maximal cytotoxicity of drugs of this class occurs during the S phase (4-6). Drugs such as and its congeners, on the other hand, apparently act by trapping the enzyme in the closed-clamp form: a DNA-bound enzyme molecule in the closed-clamp form would be prevented from transporting DNA segments, and a free enzyme molecule trapped in the closed-clamp form would be prevented from binding to DNA, as intracellular DNA has few free ends. Based on genetic analysis of top2 mutants of the yeast Saccharomyces pombe and S. cerevisiae (27) , trapping DNA topoisomerase II in the closed-clamp form is expected to affect chromosomal condensation and decondensation, and the segregation of multiply intertwined pairs of chromosomes during mitosis. Studies with mammalian cell lines show that treatment with ICRF-193 or its homologue inhibits cell cycle progression at G2-M (10, (28) (29) (30) (31) (32) and prevents chromosome segregation during anaphase (33) .
Bisdioxopiperaznes including are known to circumvent the cytotoxicity ofetoposide (10) . The trapping of the enzyme in the closed-clamp form by a bisdioxopiperazine is expected to prevent any free enzyme molecule from binding to a DNA and thus prevent any etoposide-induced formation of covalent DNA topoisomerase II-DNA complexes. Further experiments are needed, however, to determine whether the bisdioxopiperazines interfere with the action of etoposide on a DNA-bound DNA topoisomerase II and what might be the mechanism if it does.
In the protein-clamp model for type II DNA topoisomerases, during each catalytic cycle an enzyme undergoes a major reversible transition. The results presented in this communication demonstrate that a drug that interferes with this transition is cytotoxic. Because of the intricacies of this structural transition, it is likely that diverse chemical classes of inhibitors that interfere with either the forward or the reverse reaction can be found or designed; this in turn implies that the full potential of type II DNA topoisomerases as targets of antimicrobial, antiparasitic, and anticancer therapeutics is yet to be explored.
